Northern Trust Corporation Common Stock vs Twist Bioscience Corp — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $29.76B), while Twist Bioscience Corp trades at $143.94 (market cap $9.82B). The key difference: Northern Trust Corporation Common Stock is far larger — about 3× Twist Bioscience Corp's market cap, and Northern Trust Corporation Common Stock pays a 2.02% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| NTRS | TWST | |
|---|---|---|
Market Cap | $29.76B | $9.82B |
Volume | 1,427,762 | 2,115,226 |
Sector | Financials | Health |
52-Week High | $191.47 | $205.00 |
52-Week Low | $122.72 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | -$6.24B | $9.75B |
Dividend Yield | 2.02% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →